FC
LKFT

Finepoint Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Finepoint Capital’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-656,587
Closed -$16.5M – 15
2025
Q1 		$16.5M Sell
656,587
-18,175
-3% -$459K 1.26% 10
2024
Q4 		$18.6M Buy
674,762
+117,000
+21% +$3.26M 1.13% 12
2024
Q3 		$16.1M Buy
557,762
+15,000
+3% +$408K 1.17% 12
2024
Q2 		$13.4M Buy
542,762
+39,003
+8% +$1.11M 3.82% 12
2024
Q1 		$16.2M Buy
503,759
+45,100
+10% +$1.68M 4.16% 10
2023
Q4 		$18.6M Hold
458,659
– – 5.88% 9
2023
Q3 		$15.8M Buy
458,659
+51,800
+13% +$2.02M 7.89% 5
2023
Q2 		$16.5M Sell
406,859
-37,800
-9% -$1.54M 5.72% 6
2023
Q1 		$17.2M Buy
444,659
+54,300
+14% +$2.23M 6.56% 5
2022
Q4 		$17.3M Buy
390,359
+10,657
+3% +$448K 5.6% 7
2022
Q3 		$16.2M Buy
379,702
+120,302
+46% +$6.16M 5.32% 12
2022
Q2 		$14.5M Buy
+259,400
New +$15.4M 5.01% 9

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Finepoint Capital's LKFT Position: Q2 2025 in Review

Finepoint Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 656,587 shares — an estimated $16.5M sold.

Finepoint Capital first reported a position in LKFT in Q2 2022 and held it in 12 quarters. The position peaked at $18.6M in Q4 2023. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

  • Finepoint Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
  • Finepoint Capital sold 656,587 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $16.5M.
  • Finepoint Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2022 and held it in 12 quarters.
  • Finepoint Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $18.6M in Q4 2023.
  • 85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.